Healthcare
InnoCare Pharma Limited(INCPF)
Live Price
Offline$1.55
+0.00% today
1Y Change
-52.45%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $18.01B
- Revenue Growth
- +127.6%
- EPS Growth
- +238.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InnoCare Pharma Limited (INCPF) is a Healthcare stock with a market cap of $18.01B and listed on OTC. The stock last traded around $1.55 and down 52.5% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +127.6%, EPS growth of +238.5%, a dividend yield of 0.0%. What stands out right now is revenue +127.6%, EPS +238.5%, free cash flow +129.5% with operating margin 23.7% and ROIC 6.2%. Valuation sits in the middle of the pack at P/E 29.5 and price/sales 7.2. Stock Foundry combines INCPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+127.6% vs +7.6% peer median
Operating Margin
Above sector median
+23.7% vs +19.4% peer median
P/E
Below sector median
29.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +127.6% and EPS at +238.5%, with operating margin around 23.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +0.0% | +0.0% | โ |
2026 Apr 24, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Nov 13, 2025 | โ | +0.0% | -7.8% | -7.8% |
Benchmark Edge
INCPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INCPF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INCPF Max Drawdown
-52.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INCPF and SPY.
Company Overview
InnoCare Pharma Limited
Other OTC
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
- Leadership
- Jisong Cui
- IPO Date
- Jul 9, 2021
- Employees
- 1.1k
- Street Address
- Building 8
- Mailing
- Beijing, 102206
- Region
- Beijing, CN
- Reporting Currency
- USD
- Investor Line
- 86 10 6660 9999
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.5
- EV/EBITDA
- 21.2
- Price/Sales
- 7.2
- Price/Book
- 2.9
Growth
- Revenue
- +127.6%
- EPS
- +238.5%
- Free Cash Flow
- +129.5%
Profitability
- Gross Margin
- 90.4%
- Operating Margin
- 23.7%
- Net Margin
- 28.8%
- ROE
- 10.1%
- ROIC
- 6.2%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 5.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.